Most parotid gland tumors are benign, with studies consistently finding that roughly two-thirds to three-quarters of growths in this gland are noncancerous. The parotid is the largest of the three paired salivary glands, sitting just in front of and below each ear, and it accounts for the majority of salivary gland tumors overall. That said, the one-in-three chance of malignancy is high enough that any new lump near the jaw warrants prompt investigation, and the gland’s intimate relationship with the facial nerve makes both diagnosis and treatment more complex than the word “benign” might suggest.
The Most Common Types
In a five-year study of 156 parotid tumors in Romania, about 67% were benign and 33% were malignant, giving a benign-to-malignant ratio of roughly 2.6 to 1.1PubMed Central. Benign and Malignant Parotid Gland Tumors: Insights from a Five-Year Northeast Romanian Population Two benign types dominate the landscape:
- Pleomorphic adenoma: By far the most common parotid tumor, making up about 70% of benign cases in that same study. It tends to present as a slow-growing, painless lump, and it is the tumor most people picture when they hear “parotid mass.” Pleomorphic adenomas have a distinctive genetic signature involving rearrangements of a gene called PLAG1, which is consistently altered in these tumors.2Modern Pathology. PLAG1 gene alterations in salivary gland pleomorphic adenoma and carcinoma ex-pleomorphic adenoma
- Warthin tumor: The second most common benign parotid tumor, sometimes called papillary cystadenoma lymphomatosum. Unlike pleomorphic adenomas, Warthin tumors are strongly linked to smoking and occasionally appear on both sides of the face at once.
On the malignant side, the picture is more varied. Common cancerous types include mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma, and salivary duct carcinoma. Each behaves differently: adenoid cystic carcinoma is notorious for creeping along nerves and recurring years or even decades later, while mucoepidermoid carcinoma ranges from indolent low-grade forms to aggressive high-grade ones.3PubMed Central. Adenoid Cystic Carcinoma of Salivary Glands: A Ten-Year Review and an Assessment of the Current Management, Surgery, Radiotherapy, and Chemotherapy Of the malignant parotid tumors in the Romanian study, about half were actually metastatic deposits from cancers elsewhere in the body, a reminder that a parotid lump doesn’t always start in the parotid.4PubMed Central. Benign and Malignant Parotid Gland Tumors: Insights from a Five-Year Northeast Romanian Population
When a Benign Tumor Can Turn Malignant
One of the trickiest aspects of pleomorphic adenomas is their potential for malignant transformation. A cancer arising from a pre-existing pleomorphic adenoma is called carcinoma ex pleomorphic adenoma, and the risk increases with the size of the tumor and the age of the patient.5PubMed Central. Risk of Carcinoma in Pleomorphic Adenomas of the Parotid Older literature has quoted the risk of malignant change at around 1.5% for tumors present less than five years, climbing to roughly 9.5% for those present longer than fifteen years.6American Journal of Neuroradiology. Carcinoma Ex Pleomorphic Adenoma of the Parotid Gland: Radiologic-Pathologic Correlation with MR Imaging Including Diffusion-Weighted Imaging That rising curve is a major reason surgeons generally recommend removing pleomorphic adenomas rather than watching them indefinitely, even though they are benign at the time of diagnosis.
Risk Factors Worth Knowing
For most parotid tumors, there is no single clear-cut cause. But two risk factors stand out in the research.
Smoking is the most striking one, and its connection to Warthin tumor is remarkably strong. A nationwide case-control study found that people who had ever smoked cigarettes had about fifteen times the odds of developing a Warthin tumor compared to nonsmokers.7PubMed. Smoking and risk of parotid gland tumors: a nationwide case-control study Other studies have placed the relative risk at roughly eight times for smokers overall, with heavier smoking conferring higher risk and women who smoke possibly facing an even larger relative increase than men.8PubMed. Cigarette smoking and Warthin’s tumor9PubMed. Smoking as an etiologic factor in the development of Warthin’s tumor of the parotid gland This link is considered strong enough that smoking is sometimes described as the only well-established modifiable risk factor for any salivary gland tumor.
Radiation exposure is the other factor with solid evidence behind it. Therapeutic radiation to the head and neck area has long been associated with salivary gland tumors appearing years later.10PubMed. Radiation-induced salivary gland tumors: a report of 18 cases and a review of the literature A population-based study in Los Angeles found that even cumulative exposure from diagnostic radiography (dental and medical X-rays to the head) was associated with a dose-related increase in risk for malignant parotid tumors, with exposure before age twenty showing a particularly clear effect.11JNCI: Journal of the National Cancer Institute. Prior Exposure to Medical and Dental X-rays Related to Tumors of the Parotid Gland Modern dental X-rays deliver far lower doses than the equipment used when that study was conducted, but the finding underscores why radiation doses to the head have been minimized over the decades.
How Parotid Tumors Are Diagnosed
Most people first notice a parotid tumor as a painless lump in front of or just below the ear. Pain, rapid growth, or facial weakness are warning signs that raise suspicion for malignancy, though plenty of cancers present as painless lumps too. Diagnosis typically unfolds in stages: imaging first, then tissue sampling.
Ultrasound is usually the first imaging step, and MRI offers the most detailed view of the gland and its surroundings. On MRI, specific features like irregular margins, low signal intensity on certain sequences, invasion into surrounding tissue, and enlarged lymph nodes all point toward malignancy.12PubMed Central. MR imaging of parotid tumors: typical lesion characteristics in MR imaging improve discrimination between benign and malignant disease But imaging alone cannot tell you the exact tumor type. That requires a biopsy.
For years, fine needle aspiration (FNA) was the standard tissue-sampling technique. It uses a thin needle to collect cells and carries minimal risk of complications. The trade-off is that FNA has a fairly high rate of nondiagnostic or inadequate samples. Core needle biopsy (CNB), which uses a slightly larger needle to extract a small cylinder of tissue, has been gaining ground. A recent meta-analysis comparing the two methods found that CNB’s sensitivity was around 99%, far higher than FNA’s roughly 68%, while specificity was similarly high for both.13PubMed. Fine-needle aspiration or core needle biopsy? A meta-analysis of diagnostic accuracy and procedural outcomes in salivary gland tumors A direct comparison of the two in parotid masses specifically found that FNA had a nondiagnostic rate of about 20% versus only 5% for CNB, and complication rates were low and similar for both techniques, with no reported cases of facial nerve injury or tumor seeding.14PubMed Central. Comparative Outcomes of Fine Needle Aspiration and Core Needle Biopsy for Parotid Masses These results have made CNB an increasingly popular choice, though FNA remains widely used and is still appropriate in many settings.
Shear wave elastography, a newer ultrasound-based technique that measures tissue stiffness, has generated interest as a way to distinguish benign from malignant lesions without a needle at all. The idea is intuitive: malignant tissue tends to be stiffer. In practice, though, results have been mixed. One study found that while elastography could distinguish benign from malignant tumors on its own, it added little diagnostic value beyond what a standard ultrasound already provided.15PubMed Central. Differential Diagnosis of Parotid Gland Tumors: Role of Shear Wave Elastography Another concluded that it could not reliably differentiate between tumor types as a stand-alone tool.16PubMed Central. The current value of quantitative shear wave sonoelastography in parotid gland tumors For now, elastography is best considered a supplementary technique rather than a replacement for biopsy.
Surgery and the Facial Nerve
Surgery is the primary treatment for nearly all parotid tumors, benign and malignant. What makes parotid surgery uniquely anxiety-inducing for patients is the facial nerve, which runs directly through the gland, splitting it into superficial and deep lobes. Damage to this nerve can cause partial or total paralysis of one side of the face, affecting the ability to close the eye, smile, or move the forehead.
The extent of surgery depends on where the tumor sits and whether it’s benign or malignant. For small benign tumors, the trend has moved toward less radical operations. A ten-year prospective study of 205 patients found that partial superficial parotidectomy, which removes only the portion of the gland containing the tumor, produced low recurrence rates and significantly less temporary facial nerve weakness (about 10%) compared to standard superficial parotidectomy (28%) or total parotidectomy (40%).17PubMed. Partial Superficial, Superficial, and Total Parotidectomy in the Management of Benign Parotid Gland Tumors: A 10-Year Prospective Study of 205 Patients A randomized trial echoed these findings, reporting that patients who underwent the more limited procedure had fewer overall complications, better cosmetic satisfaction, and preserved more salivary function on the operated side.18British Journal of Surgery. Randomized clinical trial comparing partial parotidectomy versus superficial or total parotidectomy
For early-stage malignant tumors, a similar shift may be underway. A study comparing partial parotidectomy to more extensive procedures for small primary parotid cancers found no significant differences in recurrence or mortality, though operative time was shorter and complication rates were lower in the partial group.19PubMed Central. Comparison of Partial Versus Superficial or Total Parotidectomy for Superficial T1-2 Primary Parotid Cancers Larger or more aggressive cancers still require more extensive surgery, and sometimes the facial nerve or part of it must be sacrificed if the tumor has invaded it directly.
Intraoperative facial nerve monitoring, where the nerve is electrically stimulated during the operation to confirm it is still functioning, has become standard practice in many centers. A systematic review and meta-analysis found that monitoring reduced the rate of immediate postoperative facial weakness from about 35% to about 23%.20PubMed. Facial nerve monitoring during parotidectomy: a systematic review and meta-analysis The rate of permanent weakness, however, was not statistically different between monitored and unmonitored groups, sitting at roughly 4-7% in both. That suggests monitoring primarily helps surgeons avoid temporary stretch or compression injuries during dissection, while the rare permanent injuries may involve situations where the nerve is already compromised by tumor.
Life After Parotidectomy
Patients often worry about how they will look and feel after parotid surgery, and the honest answer is that some lingering effects are common, though most are manageable. A long-term quality-of-life study found that the most persistent complaint was numbness around the ear. Six weeks after surgery, about 77% of patients reported bothersome numbness; even thirteen years later, over half still experienced some degree of sensation loss, though its severity had decreased significantly over time.21PubMed Central. Long-term outcomes and quality of life following parotidectomy for benign disease Pain at the surgical site, by contrast, improved substantially: 77% of long-term patients reported no pain at all.
Frey syndrome is one of the more unusual complications. It involves sweating and flushing of the skin over the former parotid area whenever the person eats, especially sour or spicy foods. It happens because regenerating nerve fibers originally destined for the salivary gland instead connect to sweat glands in the overlying skin. The frequency varies with the extent of surgery and how actively clinicians test for it, but the randomized trial of partial versus conventional parotidectomy found that the more conservative approach produced Frey syndrome in only about 6% of patients.22British Journal of Surgery. Randomized clinical trial comparing partial parotidectomy versus superficial or total parotidectomy When it does occur and is bothersome enough to treat, botulinum toxin injections to the affected skin area are effective.
Cosmetic concerns, particularly a visible hollowing of the cheek where gland tissue was removed, also affect quality of life. Larger operations produce more noticeable contour changes. Comparisons across surgery types confirm that the extent of surgery correlates with how satisfied patients are with the aesthetic outcome and overall symptom burden.23PubMed. Outcome, general, and symptom-specific quality of life after various types of parotid resection Various techniques to fill the surgical defect, using local tissue flaps or fat grafts, can improve the appearance.
When Radiation Is Added After Surgery
For benign tumors, surgery alone is almost always sufficient. Malignant parotid tumors are a different story. Postoperative radiation therapy is commonly recommended when the cancer has features that increase the risk of local recurrence, such as positive or close surgical margins, spread into tissue beyond the gland, nerve invasion, or lymph node involvement.24PubMed. Postoperative radiotherapy for malignant tumors of the parotid gland
The evidence for adding radiation is strongest in tumors with high-risk features. One study of early-stage parotid cancers found that local recurrence dropped from 33% without postoperative radiation to just 3% with it, and five-year disease-free survival improved from 70% to 92%.25PubMed. Postoperative radiation therapy for T1 and T2 primary parotid carcinoma: is it useful? Even low-grade malignancies like low-grade mucoepidermoid carcinoma may benefit from radiation when pathology shows concerning features like nerve invasion or incomplete margins.26PubMed Central. Postoperative radiation therapy for parotid mucoepidermoid carcinoma For high-grade tumors, most oncologists consider postoperative radiation standard.
Targeted Therapy and Immunotherapy for Advanced Cancers
When a parotid cancer recurs or spreads beyond the reach of surgery and radiation, systemic treatment becomes necessary. Traditional chemotherapy has been disappointing for salivary gland cancers, with response rates often in the single digits. The most meaningful progress has come from targeting specific molecular features that some of these tumors carry.27PubMed. Systemic Therapy for Salivary Gland Cancers: A Review of Targeted and Chemotherapeutic Approaches
Two biomarkers have been particularly actionable. Some salivary duct carcinomas express androgen receptors, making them responsive to hormone-blocking drugs originally developed for prostate cancer. Others carry HER2 amplification, which opens the door to HER2-directed therapies borrowed from breast cancer treatment. Newer antibody-drug conjugates targeting HER2, including agents used in what’s sometimes called the “HER2-low” space, have shown favorable responses even in tumors with modest levels of HER2 expression.28PubMed. Facial palsy Revealing AR+/HER2+ Parotid carcinoma and the efficacy of HER2-Targeted therapy trastuzumab deruxtecan Response rates in these biomarker-selected groups often exceed 50%, a dramatic improvement over unselected chemotherapy.29PubMed. Systemic Therapy for Salivary Gland Cancers: A Review of Targeted and Chemotherapeutic Approaches
Immunotherapy with checkpoint inhibitors has also entered the picture, though with more measured results. A phase 2 trial of combined nivolumab and ipilimumab in 64 patients with metastatic salivary gland cancers found a 16% objective response rate in non-adenoid-cystic subtypes, but only 6% in adenoid cystic carcinoma, which tends to be immunologically “cold.”30Nature Medicine. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial Pembrolizumab, another checkpoint inhibitor, has shown an overall response rate of about 26% in a mixed cohort of recurrent or metastatic salivary cancers.31Scientific Reports. PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab A systematic review of anti-PD-1 therapies in salivary gland cancers concluded that they can be a safe option for advanced disease, though stable disease rather than shrinkage is the more typical outcome.32PubMed. The Role of Immunotherapy in Salivary Gland Cancer: A Systematic Review Molecular profiling of these tumors is increasingly important, because the best treatment depends less on the anatomic origin of the tumor and more on which pathways are driving it.
Parotid Tumors in Children
Parotid tumors are rare in children, but when they do occur the rules differ from adults. The proportion that turn out to be malignant is higher in the pediatric population.33JAMA Otolaryngology–Head & Neck Surgery. Pediatric Parotid Masses A single-center study of twelve children with parotid masses found that a quarter had malignancy, a third had benign tumors, and the remaining cases were vascular malformations or inflammatory conditions, a distribution quite unlike the adult pattern.34PubMed Central. Characteristics, Surgical Management, and Outcomes of Parotid Gland Masses in the Pediatric Age Group: A Single Tertiary Institute Experience The practical takeaway: a parotid lump in a child should not be assumed benign just because salivary tumors are “usually benign” in the general population. The differential diagnosis is broader in children, and the threshold for thorough workup should be lower.
Conditions That Can Mimic a Parotid Tumor
Not every lump in the parotid area is a tumor. One increasingly recognized mimic is IgG4-related disease, a chronic inflammatory condition that can cause swelling in various organs, including the salivary glands. When it involves the parotid, it can produce a mass that looks like a pleomorphic adenoma on ultrasound and MRI, leading to surgery that turns out not to have been strictly necessary.35PubMed Central. Synchronous occurrence of IgG4-related sialadenitis and ductal carcinoma of the parotid gland: a case report Case reports describe bilateral parotid masses initially suspected as pleomorphic adenomas that turned out to be IgG4-related disease after histopathology revealed the characteristic dense infiltration of IgG4-positive plasma cells and fibrosis.36Journal of Korean Dental Association. IgG4-related disease on parotid gland mimicking pleomorphic adenoma: Report of a case Other conditions on the differential include lymphoepithelial cysts (seen more often in people with HIV), benign lymph nodes within the gland, chronic infections, and sarcoidosis. A good biopsy and appropriate imaging usually sort these out, but the existence of convincing mimics is one more reason that tissue diagnosis matters before committing to surgery.